At its Annual Meeting of Stockholders on July 17, 2026, Artelo Biosciences, Inc. approved an amendment to its Articles of Incorporation to increase the number of authorized shares of common stock from 166,666,667 to 500,000,000. Shareholders also approved the issuance of more than 20% of issued and outstanding common stock under an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5. Additionally, Gregory R. Reyes, Tamara A. Favorito, and Gregory D. Gorgas were re-elected as Class III directors. The company is a biotechnology firm that develops therapeutic candidates for medical conditions.